Multiplex PCR-direct sequencing method was established to detect 9 different SNPs in exon 6 and exon 7 of ABO genes and could identify at least 28 different ABO genotypes. Population study was carried out in a sample of 80 unrelated Chinese Tibetan minority individual dwelled in Qinghai Province. The method was also applied to forensic cases. A variety of degeneration forensic samples, including blood stain, hair root, swab, bone and mixed stain were successfully identified by this efficient method and in conformance with serological typing. There were no significant deviations from Hardy-Weinberg equilibrium in ABO genotypes of Tibetan population. The heterozygosity, polymorphic information content, discrimination power, paternity of exclusion, and probability of genetic identity were 0.675, 0.672, 0.874, 0.391, and 0.126 respectively. The gene frequency of ABO was O>B>A. The multiplex PCR-directed sequencing method can accurately and reliably detect ABO genotypes in many kinds of samples, and it improves personal identification efficiency. The ABO genotype is high variance in Qinghai Tibetan minority group, and it can be applied in forensic medicine and population genetic study.
Download full-text PDF |
Source |
---|
Background: The Bombay and para-Bombay blood groups are rare blood types that are significant to clinical blood transfusions. Accurate para-Bombay blood group identification is important for the safety of transfusions.
Methods: Serological and molecular biology methods were used to detect one case of ABO blood type.
Clin Exp Nephrol
January 2025
Division of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Background: This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) in ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy.
Methods: FCGR3A 158F/V polymorphisms were identified in 85 ABOi or HLAi KTx recipients who underwent RTx desensitization at our institution between April 2008 and October 2021.
Cureus
December 2024
Cardiology Oncology Collaborative Research Groupe, Faculty of Medicine, University of Algiers Benyoucef Benkhedda, Algiers, DZA.
Introduction: Research on the association between blood groups and cardiovascular diseases (CVDs) in Africa, including Algeria, is notably limited, with a primary focus on blood donors. This narrow scope hinders a comprehensive understanding of the genetic diversity of blood groups and their potential links to CVD risk within the African context. To bridge this knowledge gap, this study proposes to investigate the distribution of blood group genotypes and their association with CVD prevalence, aiming to enhance knowledge within the African context and contribute to global insights into the relationship between blood groups and CVD.
View Article and Find Full Text PDFJ Thromb Haemost
December 2024
Thrombosis Research Group, Department of Clinical Medicine, UiT The Arctic University of North Norway, Tromsø,Norway; Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
Background: Atrial fibrillation (AF) is a major risk factor for ischemic stroke. Whether prothrombotic single nucleotide polymorphisms (SNPs) impact stroke risk in AF is not well known.
Objectives: To investigate the joint effects of five prothrombotic SNPs and AF on ischemic stroke risk.
Ann Med
December 2025
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Objectives: Platelet transfusion refractoriness (PTR) is a frustrating clinical problem, and primary and persistent (P/P) PTR who experienced persistent PTR since the first transfusion was failed to be well recognized. This study aims to investigate the incidence and risk factors for P/P PTR.
Methods: Patients with hematologic disorders who underwent HLA high-resolution genotyping and donor-specific HLA antibody or panel reactive antibody (PRA) testing between January 2019 and March 2023 were reviewed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!